<DOC>
	<DOCNO>NCT02020577</DOCNO>
	<brief_summary>The trial divide two part , Part A Part B . Part A involve dose-finding dose-limiting toxicity ( DLT ) MTD patient advance solid tumour . Part B involve expansion MTD 3 cohort include non-small cell lung cancer squamous histology , recurrent/ metastatic squamous cell carcinoma head neck advance solid tumour ( except sarcoma ) .</brief_summary>
	<brief_title>Trial Afatinib ( BIBW 2992 ) + Cetuximab Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion : Part A 1 . Patients must advance malignant solid tumour metastatic unresectable 2 . At least one measurable evaluable ( nonmeasurable ) lesion per RECIST 1.1 Part B 3 . Patients must : 1. measurable disease per RECIST 1.1 2. diagnosis one follow Advanced NonSmall Cell Lung Cancer Squamous Histology ( NSCLCSQ ) 2 line chemotherapy advanced/metastatic disease ( prior EGFR direct treatment permit ) Recurrent/Metastatic Squamous Cell Carcinoma Head Neck ( R/M SCCHN ) 2 line chemotherapy advance disease 1 line prior cetuximab permit . Other malignant solid tumour except sarcoma ( metastatic colorectal cancer , wild type KRAS permit ) Part A B 4 . Age 18 year old 5 . Written inform consent consistent ICHGCP guideline local law . 6 . Histological/Cytological confirm diagnosis malignant solid tumour ( exclusion sarcoma ) 7 . Advanced disease standard treatment ineffective longer effective 8 . Recovered previous therapy relate AE &lt; /= Grade 1 study entry ( except , stable sensory neuropathy &lt; /= Grade 2 alopecia ) 9 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 10 . Adequate organ function define follow criterion : LVEF &gt; 50 % within institutional value Absolute neutrophil count ( ANC ) &gt; 1500/ mm3 Platelet count &gt; 75.000/ mm3 Estimated creatinine clearance &gt; 45ml/ min Total bilirubin &lt; 1.5 time upper limit institutional normal Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &lt; 3 x upper limit institutional normal ( ULN ) ( relate liver metastases &lt; 5xULN ) Exclusion criterion : 1 . Chemotherapy , biological therapy investigational agent within 4 week prior start study treatment . 2 . Hormonal anticancer treatment within 2 week prior start study treatment ( continue use antiandrogens and/or gonadorelin analogue [ LHRH ] permit ) 3 . Radiotherapy within 4 week prior start study treatment , except follow : 1 . Palliative radiation target organ chest may allow 2 week prior study treatment , 2 . Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol . 4 . Major surgery ( judge investigator ) within 4 week start study treatment schedule surgery project course study 5 . Known hypersensitivity afatinib excipients trial drug 6 . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior start treatment . 7 . Female patient childbearing potential : 1. nurse 2. pregnant 3. use acceptable method birth control plan continue use method throughout study and/or agree submit pregnancy test require protocol . 8 . Any history concomitant condition , opinion Investigator , would compromise patient 's ability comply study interfere evaluation efficacy safety test drug 9 . Previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure . 10 . Requiring treatment prohibit concomitant medication list protocol stop duration trial participation 11 . Known preexist interstitial lung disease 12 . Any history presence poorly control gastrointestinal disorder could affect absorption study drug ( e.g . Crohn 's disease , ulcerative colitis , chronic diarrhea , malabsorption ) 13 . Active hepatitis B infection ( define presence HepB sAg and/ Hep B DNA ) , active hepatitis C infection ( define presence Hep C RNA ) and/or know HIV carrier . 14 . Prior participation afatinib clinical study , even assign afatinib treatment . 15 . Meningeal carcinomatosis 16 . Patients brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid stable dose corticosteroid least 4 week start study treatment . Any symptom attribute brain metastasis must stable least 4 week start study treatment . 17 . Any SPC list contraindication cetuximab 18 . Use alcohol drug incompatible patient participation study investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>